FDMT FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings per share estimate for 4D Molecular Therapeutics from ($3.40) to ($3.60), indicating concerns about the company's financial performance.
• The current consensus estimate for 4D Molecular Therapeutics' full-year earnings stands at ($2.84) per share, reflecting a widespread bearish outlook among analysts.
• 4D Molecular Therapeutics shares recently traded at $7.19, with a market cap of $335.77 million, and have seen a stark price variation within the past year, having a low of $2.23 and a high of $17.41.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for 4D Molecular Therapeutics in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($3.60) per share for the year, down from their previous estimate of ($3.40). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for 4D Molecular Therapeutics' FY2026 earnings at ($2.87) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million.

A number of other brokerages also recently weighed in on FDMT. Roth Capital lowered their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Barclays lowered their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group cut their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday. Finally, Chardan Capital reissued a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded up $0.01 during trading on Friday, reaching $7.27. The stock had a trading volume of 1,204,970 shares, compared to its average volume of 2,463,474. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $17.41. The firm's fifty day moving average is $4.73 and its 200 day moving average is $4.14. The stock has a market cap of $339.51 million, a price-to-earnings ratio of -2.06 and a beta of 2.83.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. BVF Inc. IL increased its position in shares of 4D Molecular Therapeutics by 70.8% during the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after acquiring an additional 1,890,647 shares in the last quarter. Millennium Management LLC boosted its stake in 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock valued at $7,913,000 after purchasing an additional 1,337,497 shares during the last quarter. Federated Hermes Inc. increased its holdings in 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after purchasing an additional 1,246,419 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after purchasing an additional 504,086 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of 4D Molecular Therapeutics by 2,084.5% in the fourth quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company's stock worth $2,500,000 after purchasing an additional 428,285 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.